May 29, 2018
Pharmacy Update: Zinbryta Discontinued
« Back to List of News
On March 2, 2018, the manufacturers of Zinbryta (daclizumab) – a drug used in the treatment of some forms of multiple sclerosis – announced that they would stop making the drug because of concerns about serious side effects.
The United States Food and Drug Administration (FDA) agreed to a 60-day period for Zinbryta to provide time for plan members to switch to other therapies. The 60-day period ended on April 30, 2018. Dispensing to patients was no longer authorized after April 30.
Member Communications: Caremark has already sent notification letters to impacted members.